Recent Updates
Recently added Catalysts
ELDN Positive Sentiment

2-Year Phase 1b Tegoprubart Preserves Kidney Function in Transplant Recipients, With Eliezer Katz, MD

Key Takeaway: The article discusses a 2-year Phase 1b study of Tegoprubart, which demonstrated its ability to preserve kidney function in transplant recipients. Led by Dr. Eliezer Katz, the trial's results indicate a potential breakthrough in post-transplant care, enhancing patient outcomes. The findings may pave the way for further research and development in this area.
Price reaction · baseline $2.19 (2026-02-06 close) · hit after-hours · 2 other ELDN headline(s) in the window, move may be shared
day 0 close · peak
-2.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Tegoprubart shows promise in preserving kidney function.
  • The study highlights significant advancements in transplant care.
  • Positive outcomes may improve quality of life for transplant recipients.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+90%
120-day peak, hindsight
Typical move
6.5%
average across 7 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
AT-1501
Phase 2 · Kidney Transplant Rejection

Full Press Release Details

Transforming Lives. One Organ at a Time.
• Overview Focus Patient Stories Clinical Trials In The News
• Science Mechanism of Action Pipeline Publications & Presentations In The News
• Team Overview Leadership Board of Directors
• Investors Overview News & Events Press Releases Events Publications & Presentations Corporate Governance Governance Overview Committee Composition Ethics Hotline Financials SEC Filings Stock Information Stock Quote & Chart Analyst Coverage Resources Investor FAQs Email Alerts Contact IR
• Culture/Careers Culture Careers
• Contact
• Focus
• Patient Stories
• Clinical Trials
• In The News
• Mechanism of Action
• Pipeline
• Publications & Presentations
• In The News
• Overview
• Leadership
• Board of Directors
• Overview
• News & Events Press Releases Events Publications & Presentations
• Corporate Governance Governance Overview Committee Composition Ethics Hotline
• Financials SEC Filings
• Stock Information Stock Quote & Chart Analyst Coverage
• Resources Investor FAQs Email Alerts Contact IR
• Press Releases
• Events
• Publications & Presentations
• Governance Overview
• Committee Composition
• Ethics Hotline
• SEC Filings
• Stock Quote & Chart
• Analyst Coverage
• Investor FAQs
• Email Alerts
• Contact IR
• Culture
• Careers
• Privacy Overview
• Necessary
• Analytics
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.

Frequently Asked Questions

What is Tegoprubart?

Tegoprubart is a treatment studied for its ability to preserve kidney function in transplant recipients.

Who led the Phase 1b study of Tegoprubart?

The study was led by Dr. Eliezer Katz.

What were the results of the Tegoprubart study?

The study showed that Tegoprubart effectively preserved kidney function over a 2-year period.

What is the significance of this study?

The study indicates a potential breakthrough in improving outcomes for kidney transplant patients.

Last updated: Feb 6, 2026